Cardiology
AstraZeneca’s heart drug failure raises a brutal question: how much treatment is too much treatment?
AstraZeneca and Ionis’ eplontersen did not reduce cardiovascular death and recurrent cardiovascular events in the overall CARDIO-TTRansform population. With 57% of participants already receiving a transthyretin stabiliser and another 24% starting one during the study, the result raises a harder question than whether one drug failed: how should regulators and payers judge added benefit when…
AlphaGenome Makes Variant Interpretation Political
AI Diagnosis Has Entered the Access Debate
Africa’s Cardiovascular Decade Is a System-Design Problem
Inherited Lipid Screening Becomes Europe’s Prevention Test
ATTR Gene Editing Restarts, But Safety Becomes the Access Question
Routine CT Scans Could Become a Heart Failure Early-Warning System
Risk Prediction Cannot Simply Be Imported From Europe
Personalised Cardiology Needs a Digital Fabric, Not Just More Data
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.